-+ 0.00%
-+ 0.00%
-+ 0.00%

Illumina (ILMN) Shares Just Moved, So What Is Driving Attention Now?

Simply Wall St·11/19/2026 15:16:26
Listen to the news

Illumina (ILMN) is back in focus after the company raised its full year 2026 revenue and earnings guidance, citing strong clinical demand for its sequencing platforms and new product announcements in molecular residual disease research.

Illumina shares tell a mixed story in the short term and a powerful one over a longer stretch. The stock has climbed 56.32% year to date on a share price basis and delivered a 74.83% total shareholder return over one year, yet the 30 day share price return declined 20.04% as investors weigh recall related cybersecurity headlines against raised guidance and strong sequencing demand.

Capitalize on the renewed focus on clinical sequencing by scanning our hand picked 37 healthcare AI stocks that are also building out data, software and diagnostics platforms around genomics and AI.

Illumina now trades well below the average analyst target, yet still reflects a strong year long run. The gap between price, targets, and intrinsic estimates is where the real work starts on valuation.

Most Popular Narrative: 20% Undervalued

Illumina's analyst consensus Narrative on Simply Wall St pegs fair value at $261.45 per share compared with the last close at $210.01. This frames the recent pullback as a discount to that modelled long term view anchored on clinical demand and data products.

The rapid transition to NovaSeq X, with more than 80 instruments placed in Q1 2026 and more than 95 in Q2 2026 and over three quarters of clinical volume already on the platform, supports expectations that an expanded installed base will keep consumables revenue and gross profit growing from this higher level.

See why 55 investors see Illumina as 20% undervalued.

Result: Fair Value of $261.45 (UNDERVALUED)

Still, Illumina's recall tied to server security and the heavy reliance on clinical consumables growth could both undermine the current undervalued narrative if those issues worsen.

Find out about the key risks to this Illumina narrative.

Next Steps

Illumina inspires both optimism and concern in this setup. Move quickly, pull up the data, and weigh the 3 key rewards and 1 important warning sign against your own expectations.

Looking for more ideas beyond Illumina?

If Illumina has your attention, do not stop there. Broaden your watchlist with other clear opportunities that match different goals and risk levels.